双歧杆菌脂磷壁酸对多发性骨髓瘤患者骨髓间充质干细胞生物学特性的影响

目的 探讨双歧杆菌脂磷壁酸对多发性骨髓瘤患者骨髓间充质干细胞增殖及细胞因子分泌情况的影响。方法 应用密度-梯度离心法分别获取多发性骨髓瘤患者及对照组骨髓间充质干细胞，应用流式细胞仪确定间充质干细胞表型，EDU法和ELISA法分别检测不同质量浓度（0.5、1.0、2.0、4.0、6.0g/L）的双歧杆菌脂磷壁酸共培养后的骨髓间充质干细胞增殖率及培养液上清中IL-17及IL-6含量变化。结果 多发性骨髓瘤患者与对照组骨髓间充质干细胞的形态及表型表达完全相同，当双歧杆菌脂磷壁酸干预质量浓度为1.0g/L和2.0g/L时，多发性骨髓瘤组间充质干细胞的增殖率显著高于正常对照组（P<0.05），质量浓度为4.0g/L和6.0g/L时，细胞增殖率反而显著低于正常对照组（P<0.05）。多发性骨髓瘤患者骨髓间充质干细胞的IL-17和IL-6水平均显著高于正常人，应用0.5、1.0、2.0和4.0g/L双歧杆菌脂磷壁酸干预后，其细胞因子的表达水平显著下降（P<0.05）。结论 一定质量浓度的双歧杆菌脂磷壁酸可以促进多发性骨髓瘤患者骨髓间充质干细胞的增殖且降低其IL-17和IL-6的表达水平。

Effects of Lipoteichoicacid Extracted from Bacillus Bifidus on Biological Characteristics of Bone Marrow Mesenchymal Stem Cells from Patients with Multiple Myeloma

Objective To investigate the effect of lipoteichoicacid extracted from Bacillus bifidus on the proliferation and cytokine secretion of bone marrow mesenchymal stem cells (MSCs)fom the patients with multiple myeloma. Methods The MSCs were obtained from patients with multiple myeloma and healthy people using the method of density gradient centrifugation andwere analysed by flow cytometry.Morever the proliferation and the expression of IL-17 and IL-6 in the culture medium of cellscocultured with different concentration (0.5,1.0,2.0,4.0,6.0g/L) of lipoteichoicacid were tested with EDU stain and ELISA respectively. Results The morphology and phenotype of MSCsfrom patients with multiple myelomawere the same as those were obtained from the controls.The proliferation rate of MSCs in the multiple myeloma group was significantly higher than the normal group when the concentrationwas 1.0g/L and 2.0g/L(P<0.05). However,it showed opposite performancewhen the concentrationwas 4.0g/L and 6.0g/L(P<0.05). The expression of IL-17 and IL-6 were significantly higher than those in control group, andwere also significantly decreased after treated with lactobacilluswith different concentration (0.5,1.0,2.0,4.0,6.0g/L). Conclusion A certain concentration of bifidobacterium acid can promote the proliferation of MSCs and decrease the expression of IL-17 and IL-6 in patients with multiple myeloma.